The nasal influenza vaccine FluMist (MedImmune) is now approved to include children between two and five years of age. Approval had previously been limited to healthy children five years of age and older and to adults up to age 49. The vaccine contains a weakened form of the live virus and is sprayed into the nose.
Raltegravir tablets (Isentress, Merck) have been approved for the treatment of human immunodeficiency virus drug (HIV)-1 infection, in combination with other anti-retroviral agents, in patients who have received other therapies and who have evidence of viral replication and HIV-1 strains that are resistant to multiple antiretroviral agents.
The FDA has approved besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb), a topical eyedrop for patients with nonviral bacterial conjunctivitis.
Bacterial forms of conjunctivitis are common in childhood, but they can occur in people of any age. Symptoms can include reddened eyes, swelling, eyelids sticking together, itching, watering, and a sticky discharge from the eyes. The course usually lasts for 7 to 14 days.
The FDA has approved four vaccines to protect the population against the 2009 pandemic H1N1 influenza virus. About 45 million doses should be available at 90,000 sites in October. The government has ordered 195 million doses. CSL Ltd., MedImmune LLC, Sanofi-Pasteur, and Novartis Vaccines/Diagnostics Ltd. are using the same processes to make the H1N1 vaccines. Based on preliminary data, the 2009 H1N1 vaccines induce a robust immune response in most healthy adults eight to 10 days after a single dose. Clinical studies are under way to determine the optimal dose for children.
An advisory panel of the FDA has recommended stronger warnings for the influenza drug zanamivir (Relenza, Glaxo-SmithKline). The panel wanted the label to mention the potential for abnormal psychiatric side effects, sometimes leading to death. The panel also recommended additional warnings for oseltamivir (Tamiflu drug, Roche).
The panel reviewed a small but rising number of cases, mostly in Japan. In the case of generic Tamiflu, erratic behavior, including jumping from buildings, resulted in deaths. The FDA described reports of approximately 700 cases of psychiatric adverse events for both drugs and 25 cases of pediatric deaths in patients taking (buy) Tamiflu. No fatalities were reported for Relenza.
Canadian Pharmacy Blog